Extensive-Stage Small Cell Lung Cancer: Preventive Radiotherapy to the Brain and Primary Tumor Site

Prophylactic Cranial Irradiation (Brain Prophylaxis)

Question: After a very good first-line response in extensive-stage (thorax-confined) small cell lung cancer, should prophylactic cranial irradiation (PCI) be performed? What are its advantages and disadvantages ? Is there a survival benefit ? What did the “Japanese study” show?

Background: Small cell lung cancer (SCLC) carries a high risk of brain metastases . Even without brain metastases at diagnosis, this risk in extensive-stage disease, particularly within the first year, may reach 60–70%. PCI can reduce this risk in absolute terms by 20–40%. However, with the immunotherapy era , PCI's survival benefit has come into question.

For many years, particularly in extensive-stage disease responding to initial treatment, prophylactic cranial irradiation (PCI) to prevent brain spread was the standard approach .

• Potential Benefits (Pros): PCI's main advantage is a substantial reduction in brain metastasis risk. For example, a phase 3 trial published in The Lancet in 2015found that in extensive-stage SCLC patients receiving PCI, symptomatic brain metastasis incidence fell to 15%, compared with 40% without PCI. With this protection, 1-year survival reached 27% with PCI versus 13% without it. This historic study showed that PCI nearly doubled first-year survival and was therefore adopted for many years as standard care .
• Potential Risks and Disadvantages (Cons): PCI's main disadvantage is its potential neurological and cognitive adverse effects , particularly in older patients. Brain irradiation may cause memory and concentration problems as late effects. Daily radiotherapy sessions may also be challenging for this age group. Current evidencequestions routine PCI's survival effect: A Japanese phase 3 study (Takahashi et al., Lancet Oncol 2017) assigned extensive-stage patients with good responses and close MRI surveillance to observation instead of PCI . In this study, PCI did not extend overall survival – median survival was 11.6 months with PCI and 13.7 months with observation, a nonsignificant difference (HR=1.27, p=0.094). Thus, with regular brain MRI surveillance, no survival increase from PCI was demonstrated. Nevertheless, PCI remained effective in preventing brain metastases : Brain metastases developed during follow-up in 48% with PCI versus 69% without PCI (p < 0.0001). With intensive MRI surveillance, metastases in the non-PCI arm were detected early and 83% received brain irradiation (46% in the PCI arm also required brain RT). Adverse effects in the Japanese study included Grade 3-4 anorexia (6%) and weakness (3%) at month 3 after PCI, but no serious treatment-related deaths occurred. The findings indicate that if regular MRI surveillance is available , in extensive-stage disease, PCI is not “absolutely necessary” and brain metastases can be treated if they develop. Furthermore, according to ACS and NCCN guidelines, over 70 years of age or in vulnerable patients, decisions require caution because of neurocognitive effects.

Conclusion and Recommendation: PCI decisions should be individualized according to age, performance status and surveillance access. In an older patient with a clear brain MRI, weigh risks and benefits carefully. If patients and families accept, to reduce brain metastasis risk , a degree of uncertainty about survival and potential cognitive adverse effects , PCI may be considered. Alternatively, regular brain MRI every 3 months with immediate treatment if metastases develop is an evidence-based strategy.

In recent years, many centers, particularly for older extensive-stage SCLC patients with good responses, through shared decision-making have preferred to omit PCI. Japanese trial findings influenced this, and guidelines have adopted a more flexible position . For example, the NCCN guideline now presents PCI as an option and does not recommend it in patients with poor performance status or existing neurocognitive impairment .

Summary: PCI significantly reduces brain metastases, but a survival benefit has not been demonstrated with MRI surveillance. Particularly in older patients, PCI's potential cognitive harms mean that close MRI surveillance should be seriously considered.

Consolidative Radiotherapy to the Primary Tumor (Thoracic Irradiation)

Question: After an excellent response to immunochemotherapy (carboplatin-etoposide + atezolizumab) in unresectable, thorax-confined extensive-stage SCLC , should the primary tumor and mediastinum receive consolidative radiotherapy? If so, SBRT (stereotactic body radiotherapy) or conventional fractionation? What are its effects on 1-year disease-free survival and overall survival ?

Background: After systemic treatment of extensive-stage SCLC, intrathoracic residual disease often remains, and most cases recur within the chest during the first year. Although checkpoint inhibitors such as atezolizumab improve systemic control, local chest control remains challenging in some patients. Consequently, consolidative thoracic radiotherapy (TRT) has been investigated after systemic response.

Evidence-Based Benefits: Published in The Lancet in 2015, the phase 3 CREST trialassigned extensive-stage SCLC patients responding to the initial 4-6 platinum-etoposide cycles to 30 Gy/10 fractions of thoracic irradiation + PCI or PCI alone. Both arms thus received PCI, with thoracic RT added experimentally.

• Disease Control (PFS) Effect: TRT substantially slowed disease progression. Progression risk fell significantly (HR=0.73, p=0.001). At month 6, relapse-free survival was 24% with RT versus 7% in controls (17% difference). Intrathoracic recurrence was 19.8% with RT versus 46% in controls – local recurrence risk was halved.
• Survival Effect: 1-year survival was 33% with RT versus 28% in controls (p=0.066). However, 2-year survival was 13% with RT versus 3% in controls , with the 10% difference statistically significant (p=0.004). Long-term survival improvement was evident.
• Tolerability and Adverse Effects: The 30 Gy regimen was generally well tolerated. No difference in serious toxicity was identified. The most common was Grade 3 fatigue (11%). In a 2023 Italian observational study, 66% had no progression within the irradiated field, and treatment was largely completed without difficulty.

Based on these findings, researchers recommend adding thoracic radiotherapy to standard care. Current international guidelines also recommend, in extensive-stage disease confined to the thorax or with controlled metastases , TRT on an individual basis . This is particularly important with bulky mediastinal disease or residual tumor .

SBRT or Conventional Fractionation?

If TRT is given, the technique and dose matter. The CREST regimen of 30 Gy / 10 fractions was found to be safe and tolerable . Some centers also use 45 Gy / 15 fractions .

SBRT (stereotactic body radiotherapy) is suitable in early-stage SCLC as an alternative to surgery. Extensive-stage disease, however, generally requires irradiation of multiple areas . SBRT should be considered only for small, solitary lesions away from critical structures .

SBRT's advantage is a short treatment course. Its disadvantage is that high doses , near structures such as bronchi, major vessels or the esophagus, carry serious risks. Therefore, conventional RTis more appropriate for multiple sites or central disease. If there is a single, isolated small tumor focus , a multidisciplinary board may also consider SBRT.

Conclusion and Recommendation

Evidence shows that adding radiotherapy to the primary tumor delays recurrence and improves some patients' long-term survival chances .

Treatment planning should reflect the patient's overall condition : Even for an older patient with possible comorbidities, a 2-week 30 Gy regimen is generally tolerable, making this standard approach a reasonable option.

SBRTmay, with a limited target and a patient unable to attend prolonged sessions , be considered as an alternative ; however, high doses require careful patient selection.

Thus, consolidative primary-site RT in this setting may be beneficial; administration decisions should consider tumor extent, patient tolerance and center experience .

Patients should be clearly informed that this approach may improve 1-year disease-free survival substantially (particularly within the first 6 months, greatly reducing progression risk) and contribute to longer-term survival .

Furthermore, atezolizumab maintenance combined with RT has limited data, but existing studies report no serious adverse interaction – thus, RT may be used during immunotherapy when appropriate.

Overall Assessment

In summary, decisions about brain prophylaxis should be individualized; thoracic consolidative radiotherapy should be considered for extensive-stage SCLC with a good response and residual thoracic disease .

This combined approach can reduce both distant metastasis risk (through PCI) and local recurrence risk (through thoracic RT), increasing the chance in appropriate patients of longer disease-free and overall survival .

Both decisions should consider age, performance status and patient preferences ; the multidisciplinary team should inform the patient and develop an individualized treatment plan .